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Abstract 
Research into psychiatric disorders has long been hindered by the lack of appropriate models. 
Induced pluripotent stem cells (iPSCs) offer an unlimited source of patient-speciﬁc cells, which in 
principle can be differentiated into all disease-relevant somatic cell types to create in vitro models of 
the disorder of interest. Here, neuronal differentiation protocols available for this purpose and the 
current progress on iPSCs-based models of schizophrenia, autism spectrum disorders and bipolar 
disorder were reviewed. We also discuss the impact of the recently developed CRISPR/Cas9 genome 
editing tool in the disease modeling ﬁeld. Genetically engineered mutation of disease risk alleles in 
well characterized reference “control” hPSCs or correction of disease risk variants in patient iPSCs 
has been used as a powerful means to establish causality of the identiﬁed cellular pathology. 
Together, iPSC reprogramming and CRISPR/CAS9 genome editing technology have already 
signiﬁcantly contributed to our understanding of the developmental origin of some major psychiatric 
disorders. The challenge ahead is the identiﬁcation of shared mechanisms in their etiology, which 
will ultimately be relevant to the development of new treatments. 
 
INTRODUCTION 
Neurodevelopmental disorders are a group of conditions typically manifest early in life and are 
characterized by developmental deﬁcits that produce impairments of personal, social, academic or 
occupational functioning. Neurodevelopmental (or neuropsychiatric) conditions include autism 
spectrum disorders, intellectual disabilities, schizophrenia and bipolar disorder, and have a 
substantial genetic component (7, 19, 66, 104). 
For a long time, psychiatric research mainly relied on post-mortem studies and animal models. The 
ﬁrst approach has the major limitation of representing the end-stage of the disease, without being 
informative about its origin and pathological progression. More-over, changes observed in post 
mortem tissues may be secondary effects of a patient’s prolonged use of medications. Animal 
models, predominantly rodents, are available for several psychiatric disorders, especially autism 
spectrum disorders and schizophrenia, but they have so far failed to show signiﬁcant predictive 
validity for drug discovery (56, 71). This may be because of the inability of model organisms to 
represent unique higher human functions and consequently, to recapitulate all the symptoms 
characterizing a particular disorder (63). For example, despite the numerous rodent models available 
for schizophrenia, these are mostly representative of the psychotic aspects of the disease, but do 
not reliably reproduce the cognitive and negative symptoms, such as impaired working memory, 
anhedonia and social withdrawal (37). In the case of bipo-lar disorder, there are no animal models 
available to represent both the manic and depressive extremes characterizing the disorder (11). 
 In just a decade from the derivation of the ﬁrst line (84, 85), induced pluripotent stem cells (iPSCs) 
have become a fundamental tool for modeling human development and diseases, as well as for drug 
discovery. Like their mouse counterparts, human iPSCs are believed to have the same self-renewal 
and pluripotency properties of human embryonic stem cells (hESCs), but are derived 
(reprogrammed) from somatic cells, such as skin ﬁbroblasts (84), keratinocytes (1), dental pulp (86, 
98) or blood (48). The reprogramming is achieved by forcing the expression of key pluripotency 
genes such as OCT4, SOX2, c-MYC andKLF4insomatic cells, where the reprogramming factors start a 
self-regulatory loop that initiates and maintains pluripotency (58, 67). Expression of these 
reprogramming factors can be induced via viral transduction (6, 69), transfection of polycistronic 
plasmids (61), mRNAs (92) or direct delivery of recombinant proteins (103). More-over, treatment 
with speciﬁc combinations of small molecules has been shown to greatly increase the 
reprogramming efﬁciency (32, 78). 
The use of adult somatic cells as starting material means that iPSCs are free from the ethical 
concerns that surround the use of hESCs, and that they can be derived from individuals carrying 
genetic variants that predispose to an increased risk of human dis-eases. Working on iPSCs, and PSCs 
in general, has become increasingly important in psychiatric research thanks to the ability to study 
the consequences of a large number of disease-associated mutations in the phenotypically relevant 
cell types. This is playing an important role in advancing our understanding of the cellular 
mechanisms underlying psychiatric disorders and reinforcing the hypothesis of their developmental 
origin. 
 
GENERATION OF DISEASE RELEVANT NEURONAL CELL TYPES FROM HUMAN PSCS 
The brain contains thousands of neuronal types that differ in terms of neurotransmitter identity, 
electrophysiological properties and afferent/efferent connectivity (62). Different neurological 
diseases often exhibit pathologies speciﬁc to certain brain regions and/or cell types. This means that 
the possibility of observing and, there-fore, being able to correct a speciﬁc phenotype, is strictly 
dependent on the presence of the appropriate neuronal type in the system used. Therefore, an 
important consideration in modeling human neurological diseases is the generation of neural cell 
types targeted by the disease of interest. 
A number of neuronal cell types have been implicated in psychiatric disorders: cortical projection 
neurons (23), inhibitory inter-neurons (23, 44), hippocampal neurons (25), dopaminergic neurons 
(23) and striatal medium spiny neurons (26, 80). Protocols to generate these neuronal types have 
been developed and are reviewed in this paragraph. Many lines of evidence demonstrate that in 
vitro PSC differentiation, to a large extent, mimics vertebrate development. In the context of 
neuronal conversion, PSCs ﬁrstly exit the pluripotent state and acquire a neuroectoderm fate. 
Therefore, the majority of neuronal differentiation protocols start with the induction of a speciﬁc 
regional neuroepithelial phenotype (region-speciﬁc progenitors) from which the target cells arise. 
This is mostly achieved by artiﬁcially recapitulating the signaling environment that the region-
speciﬁc progenitors normally experience in vivo, by adding an appropriate combination of 
“inductive” molecules. The aim is to induce a cascade of transcription resembling normal 
development, leading to the expression of a combinatorial set of transcription factors characteristic 
to the desired neural progenitor phenotype. 
Currently, a popular method for generating neural cells from hPSCs is via monolayer differentiation 
protocol by dual SMAD inhibition (14). Normal central nervous system development follows an 
anterior ﬁrst–posterior later temporal fashion. As such, the ﬁrst neuroepithelial cells generated from 
PSCs exhibit features of forebrain regional identity. These anterior progenitors readily mature into 
neurons with predominantly cortical glutamatergic identity (9, 24, 79). Cell types of all cortical layers 
appear in a sequence reminiscent of in vivo corticogenesis, from deep layers to superﬁcial ones. The 
efﬁciency of this approach was shown to be very high, with glutamatergic neurons accounting for 
80% to nearly 100% of the cells in culture. 
The speciﬁcation of the other neuronal fates requires the use of additional morphogens to mimic the 
in vivo environment of the corresponding brain region. For example, the derivation of GABAergic 
interneurons requires the activation of sonic hedgehog (SHH) signaling (46, 47), in some cases 
combined with WNT inhibition (57, 64), to induce the medial ganglionic eminence (MGE) fate 
demonstrated by the expression of transcription factor NKX2.1. However, despite the induction of a 
high percentage of NKX2.11 MGE-like progenitors, efﬁcient generation of mature interneurons, 
including the two major subtypes, somatostatin (SST) and parvalbumin (PV), have so far proved 
challenging. On the other hand, caudal ganglionic eminence (CGE)-derived interneurons expressing 
calretinin have been derived with a higher efﬁciency (>70%), by exposing late neural progenitors to 
activin A, a member of the TGF-b superfamily (13). 
When applied to forebrain neural progenitors at an earlier time window, activin A induces the 
speciﬁcation of a lateral ganglionic eminence (LGE) fate, leading to the production of 40%–50% of 
medium spiny neurons (4). Other strategies for deriving this type of neurons rely on the use of SHH, 
alone or in combination with WNT inhibition (45, 49, 65), in a similar way to MGE protocols. 
Dopaminergic neurons, which are born in the ventral midbrain, can be differentiated from hPSCs by 
exposing the neural precursors to different combinations of WNT agonists with SHH (20, 39, 41) or 
FGF8 (96). In addition, FGF signaling blockade using an ERK/MEK inhibitor on exit of pluripotency, 
followed by addition of SHH and FGF8 has also been reported to induce authentic mid-brain 
dopamine neurons (34). The yield of tyrosine hydroxylase positive cells is elevated in all these cases, 
reaching above 80%. Finally, only one protocol has been reported so far for the production of 
hippocampal neurons (101). For these cells, the application of WNT3a and BDNF to dorsal forebrain 
progenitors seems to be essential to induce the expression of PROX1, a marker for dentate gyrus 
hippocampal neurons. 
Monolayer differentiation has proved itself a highly efﬁcient and reliable paradigm for generating a 
number of neuronal types. Indeed, monolayer based forebrain glutamatergic neuron differentiation 
has been the platform of choice for the majority of disease modeling articles published so far (10, 
11, 15, 30, 38, 53, 74, 77, 81, 94, 100). However, the monolayer culture system has limitations in 
visualizing potential alterations in the cytoarchitecture of the derived “brain tissue.” This 
shortcoming can be overcome, to a certain extent, by differentiating PSCs in three-dimensional (3D) 
structures called organoids (43, 55, 72), although at the expense of higher variability, both within 
and between organoids, and in different preparations. To date, only Mariani et al have used 
telencephalic organoids for analyzing the developmental abnormalities with iPSCs derived from 
patients with idiopathic autism (54). 
The generation of “induced neurons” (iNs) by direct reprogramming represents an alternative to 
conventional PSC neural differentiation. iNs are produced by forcing the expression of a deﬁned set 
of transcription factors crucial for the acquisition of neuronal fate in somatic cells or PSCs (2, 31, 42, 
68, 99). iN protocols for the generation of speciﬁc neuronal types have also been published (12, 17, 
70, 83, 89, 97). However, the iN approach may not be suitable for modeling diseases where 
pathogenesis occurs at neural progenitor stage, because it bypasses the process of neural progenitor 
speciﬁcation, proliferation and differentiation choice toward distinct neuronal and glial fates. 
Moreover, in contrast to hPSC neural differentiation, the number of iNs that can be generated from 
the donor somatic cells is limited because of the restricted proliferative capacity of somatic cells 
prior to senescence. These shortcomings combined may explain why there are no studies published 
to date using iN technology to model psychiatric disorders. 
 
CURRENT STATUS OF IPSCS-BASEDRESEARCH FOR PSYCHIATRICDISORDERS 
Brain imaging studies have demonstrated changes in the anatomy and neuronal activity in patients 
suffering from psychiatric disorders, while post-mortem studies have revealed aberrant cell-lar 
morphology (8, 22, 33, 95). The iPSC technology has provided an invaluable tool to investigate the 
cellular basis of such alterations and elucidate the molecular pathways that may be targeted for drug 
discovery. 
The ﬁrst proof-of-principle study using iPSCs was published by Brennand et al in 2011 (11). The 
authors reported that neurons derived from schizophrenic patients’ iPSCs differ from those of the 
controls in neuronal connectivity, morphology and gene expression. This work was followed by 
several other schizophrenic iPSC studies reporting the emergence of earlier developmental 
abnormalities. 
Robicsek et al differentiated schizophrenia and control iPSCs into glutamatergic and dopaminergic 
neurons and found defects in the maturation of both cell types, with the dopamine lineage more 
severely affected (74). The authors also reported differences in mitochondrial distribution and 
function. This aspect of the phenotype was more pronounced in dopaminergic progenitors than the 
glutamatergic cells. This could suggest the presence of a higher vulnerability for dopamine cells to 
oxidative stress, but it could also reﬂect, at least in part, their extremely impaired maturation. 
Together with alterations of mitochondrial membrane potential and neuronal morphology, other 
defects often reported in neuronal cells from schizophrenic patients iPSCs are relative to WNT 
signaling and migration (10, 88) (see also Table 1). 
All the studies listed above were based on heterogeneous cohorts of schizophrenic patients, 
selected only on the basis of their diagnosis, without knowledge of their genetic risk variants. This 
probably played a signiﬁcant part in the high experimental variability evident in some of the results. 
It is known that schizophrenia has a strong genetic component, with rare Copy Number Variations 
(CNVs) signiﬁcantly increasing the risk of developing this disorder [reviewed by Kirov (40)]. Strat-
ifying patients based on the presence of speciﬁc genetic mutations could help to reduce the degree 
of variability associated with iPSC work and discover new mechanisms that otherwise may be 
masked by the heterogeneity of the patients’ samples. 
Wen and colleagues took the genetics orientated approach by analyzing the effect of Disrupted In 
SChizophrenia 1 (DISC1) mutations, which are known to co-segregate with major psychiatric illnesses 
(60, 94). iPSC lines were derived from two patients carrying the same frameshift mutation in the 
DISC1 gene and three unaffected individuals. The authors reported altered morphology and 
electrophysiological properties in DISC1 neurons, as well as the expression of genes related to 
synaptic transmission, neural development and major mental disorders. They also established the 
causality between DISC1 mutations and the changes observed by repeating some of the analysis in 
several isogenic cell lines. These were derived by correcting the DISC1 mutation in one of the mutant 
lines and by introducing the same frameshift deletion present in patients in two control lines. Both 
synaptic and vesicular release properties were restored to normal levels in the cell line in which the 
DISC1 gene sequence had been corrected, while the control lines carrying DISC1 deletion 
recapitulated the original mutant phenotype. However, the majority of CNVs associated to 
psychiatric disorders contain multiple genes. This genetic feature makes iPSC modeling particularly 
advantageous over the generation of animal models. Microdeletion of the 15q11.2 locus has been 
reported by several studies as an important risk factor for schizophrenia (82, 87). Yoon and 
colleagues demonstrated that iPSCs derived from 15q11.2 deletion carriers had signiﬁcant defects in 
neural rosette formation (100). The 15q11.2 region contains four genes, CYFIP1 was proposed to be 
the likely responsible gene for the observed phenotypes. Indeed, increasing CYFIP1 expression by 
lentiviral transduction in differentiating 15q11.2del iPSCs rescued the abnormal expression of apical 
polarity markers, while reduction of CYFIP1 expression by shRNA in a control line mimicked the 
phenotype observed in the deleted progenitors. The authors extended their quest into CYFIP1 
function by shRNA knockdown of Cyﬁp1 in mouse embryos via in utero electroporation, which 
resulted in incorrect localization of radial glia cells and nascent neurons. However, the consequences 
of CYFIP1 disruption in post-mitotic neurons were not explored. 
As for autism spectrum disorders, in vitro modeling was ﬁrst applied to syndromic autism, such as 
Rett syndrome (RTT) and Phelan-McDermid syndrome (PMDS). RTT syndrome is one of the most 
common causes of mental retardation mainly affecting girls and is caused by mutations of the 
methyl CpG binding protein 2 (MECP2) (3). iPSCs based investigations into RTT reported defects in 
neuronal maturation in patients’ cells (38, 53) (see also Table 1). In particular, Marchetto et al 
demonstrated the presence of morphological alterations and reduced number of glutamatergic 
synapses in RTT neurons (53). This defect could be rescued by IGF1, a neurotrophic factor capable of 
promoting synaptogenesis. The same group subsequently reported the involvement of MeCP2 in 
regulating the expression of TRPC6, one of the genes disrupted by a translocation recently found in 
an autistic patient (30). 
Similar cellular phenotypes were reported in in vitro models of PMDS. Shcheglovitov et al 
investigated the cellular phenotypes of iPSCs-derived neurons from two patients carrying 
heterozygous deletion of chromosome 22q13.3, the mutation responsible for PMDS (77). Cortical 
neurons derived from these iPSCs displayed impaired excitatory synaptic transmission, while the 
properties of their inhibitory synapses were not affected. These deﬁcits could be either rescued by 
increasing the expression of SHANK3, a gene included in the deleted locus, or by IGF1 treatment, 
which did not affect SHANK3 levels. 
Taking a different approach, Mariani et al derived iPSCs from four probands with idiopathic autism, 
carrying no known genetic mutation previously associated with autism spectrum disorders, and 
unaffected family members (54). Transcriptomic analysis of telencephalic organoids derived from 
patients and control cells revealed many differentially expressed genes, mainly relative to cell fate, 
proliferation, axonal guidance, synaptic function and ion channels. Consistently with these results, 
probands’ cells showed dysregu-ated cell cycle and overproduction of inhibitory neurons, a 
phenotype that could be rescued by attenuating FOXG1 levels. 
In the context of bipolar disorder, after performing a microarray analysis of iPSC-derived neurons 
from three patients and three controls, Chen and colleagues found a similar alteration in the 
expression of transcription factors regulating dorsoventral telencepahlic patterning (15). These 
results, however, do not signiﬁcantly overlap with those from Mertens et al, the only other 
publication employing iPSCs for bipolar disorder modeling to date (59). Their work, based on 
hippocampal neurons derived from bipolar patients, showed that the hyperexcitability and abnormal 
mitochondria size of these cells could be rescued by lithium treatment, while alteration of 
mitochondrial membrane potential could not be improved. 
 
 
 
In the interest of space, Table 1 summarizes the above works together with additional studies not 
individually discussed in this mini review. It is evident that differences exist between studies within 
the context of the same disorder. These discrepancies may attribute to different differentiation 
protocols, culture systems and analysis methods. Nevertheless, some common themes emerge from 
these studies. In general, genes involved in nervous system development are reported to be affected 
by many studies and, in line with this, several phenotypes are already present at the neural 
progenitor stage. In particular, altered WNT signaling and mitochondria dysfunction seem to be 
frequently reported in patient-derived cells (10, 11, 59, 74, 81, 88, 90). They may represent shared 
mechanisms in the etiology of neurodevelopmental psychiatric disorders. 
 
CRISPR-BASED GENOME EDITING AS A POWERFUL ALTERNATIVE TO 
MODELNEURODEVELOPMENTAL DISORDERS 
 
iPSCs represent a virtually unlimited and bankable source of patient-speciﬁc cells that can be 
differentiated into many disease-relevant neuronal types. Therefore, they allow the investigation of 
cellular phenotypes in cohorts of patients sharing a speciﬁc genetic mutation or the same clinical 
manifestation with unknown genetic background. This is particularly advantageous in the context of 
those disorders for which a genetic cause has not been identiﬁed, such as idiopathic autism cases 
(5). However, iPSC-based studies can suffer from high variability because of the differences in the 
genetic background of different patients, reprogramming methods and culture conditions (75). 
Working with genetically modiﬁed hESCs or a well characterized reference line of hiPSCs and their 
isogenic controls can represent an alternative to the use of patient iPSCs. This strategy will avoid the 
variability linked to the different genetic backgrounds of distinct patient iPSC lines and reduce the 
necessary work load of studying multiple patient iPSC lines required for identifying true phenotype 
and establish causality. 
The CRISPR (Clusters of Regularly Interspaced Short Palindromic Repeats)/Cas9 technology allows 
genome editing more easily and efﬁciently than traditional gene targeting via Homologous 
Recombination (18, 21, 52, 73). CRISPR/Cas9 is a type II CRISPR system [reviewed by Makarova et al 
(51)], which is naturally present in many bacteria as an immunity mechanism to protect them against 
foreign DNA (27, 35). It consists of the Cas9 nuclease and a guide RNA (gRNA), a chimeric RNA 
molecule combining a CRISPR RNA (crRNA) and a transactivating RNA (tracrRNA), which together 
direct the Cas9 to cleave the target DNA sequence. This mechanism also requires the presence of a 
protospacer adjacent motif (PAM) upstream of the binding region (35). As a genome editing tool, 
CRISPR/Cas9 can be used to target virtually any genomic sequence next to a PAM site, by simply 
designing appropriate gRNAs. The generation of a double strand break (DSB) by the Cas9 induces 
cellular DNA repair mechanisms, like non-homologous ends joining (NHEJ), which is likely to 
introduce indels disrupting the targeted DNA sequence, or homology directed repair (HDR), if a 
donor construct is present. This system has been optimized for its application to human cells, 
including hPSCs, by transfecting a single or multiple vectors to co-express the Cas9 nuclease and the 
gRNAs (16, 18, 36, 52). As an alternative to the generation of a DSB by the wild type Cas9 enzyme, a 
mutated nickase version has also been developed, to facilitate HDR and reduce off-target mutations 
(18). Delivery of the CRISPR/Cas9 components via lentiviruses (76, 91), or adenoviruses (50), has also 
shown a high efﬁciency in targeting the human genome. To further improve the ﬂexibility and 
rapidity of genome editing in hPSCs, Danwei Huangfu’s group developed the iCRISPR platform, 
consisting of hESCs lines with doxycycline-inducible Cas9 expression (indicated as iCas9) (29). 
Transfection of iCas9 cells with gRNAs, derived via in vitro transcription, lead to over 40% efﬁciency 
for single gene targeting or around 10% for triple gene targeting. 
Genome editing technologies are evolving fast and, as previously discussed, they represent a valid 
alternative to the use of iPSCs, because of the reduced variability associated with the use of isogenic 
cell lines. Alternatively, CRISPR/Cas9 could also be used to correct a speciﬁc genetic mutation in 
patient-derived cells. In this case, the rescue of the phenotype would provide the deﬁnitive proof of 
the connection between disease and genotype. When investigating the effects of CNVs including 
several genes, the creation of isogenic models would be excessively time consuming, but it should at 
least be considered to conﬁrm the causality link between the gene(s) of interest within a CNV and 
the phenotype observed in differentiated iPSCs. In conclusion, the careful planning of in vitro 
modeling experiments and parallel use of engineered hESCs and iPSCs, allows the generation of very 
elegant systems for the investigation of the cellular pathology underlying complex 
neurodevelopmental disorders. 
CONCLUDING REMARKS 
Patient iPSC-based disease modeling has in a short time already shed light on the cellular pathology 
and molecular basis of neuropsychiatric disorders. This experimental model holds great promise 
despite the limitations discussed. We anticipate that CRISPR/CAS9 mediated genome editing of 
disease risk alleles in hPSCs will become a popular alternative in the disease modeling ﬁeld, 
especially for diseases with monogenic mutations. For CNVs involving multiple genes, genome 
editing provides a means to demonstrate causality underpinning phenotype. Fully harnessing the 
potential of PSC-based disease modeling will beneﬁt from the development of network models that 
contain different neuronal cell types (eg, cortical projection neurons and interneurons) and 
nonneuronal cells (eg, glial), and the improvement of high throughput culture systems for efﬁcient 
drug screening. 
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